Comparative Pharmacology
Head-to-head clinical analysis: BENOXINATE HYDROCHLORIDE versus ZTLIDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENOXINATE HYDROCHLORIDE versus ZTLIDO.
BENOXINATE HYDROCHLORIDE vs ZTLIDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium channel blocker; stabilizes neuronal membrane and prevents initiation and transmission of nerve impulses.
ZTLIDO (lidocaine) is a sodium channel blocker that binds to voltage-gated sodium channels in neuronal membranes, stabilizing the membrane and inhibiting the initiation and conduction of nerve impulses, thereby producing local anesthesia.
1-2 drops of 0.4% solution in the conjunctival sac up to every 5-10 minutes for surface anesthesia, not exceeding 7 doses per procedure.
1.8% lidocaine topical patch: Apply up to 3 patches at once to intact skin for up to 12 hours in a 24-hour period.
None Documented
None Documented
2.5-3.5 minutes in plasma; extremely short half-life due to rapid hydrolysis by plasma esterases, limiting systemic exposure after ocular administration
Terminal elimination half-life is 1.5 to 2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours with CrCl <30 mL/min).
Primarily renal; approximately 70-80% excreted unchanged in urine; minor biliary/fecal elimination (<10%)
Primarily renal excretion as unchanged drug (80-85%) and metabolites (10-15%); less than 5% excreted in feces.
Category C
Category C
Topical Anesthetic
Topical Anesthetic